Suppr超能文献

兔抗胸腺细胞球蛋白:西罗莫司治疗的肾移植患者术后的危险因素?

Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients?

作者信息

Benavides C, Mahmoud K H, Knight R, Barcenas C, Kahan B D, Van Buren C T

机构信息

University of Texas Medical School at Houston-Division of Immunology and Organ Transplantation, Houston, Texas 77030, USA.

出版信息

Transplant Proc. 2005 Mar;37(2):822-6. doi: 10.1016/j.transproceed.2004.12.121.

Abstract

AIMS

Randomized controlled studies suggest an increased incidence of perioperative wound complications among sirolimus-treated renal transplant patients. The present study analyzed the effect of rabbit antithymocyte globulin (rATG) on these postoperative complications.

METHODS

Four hundred and twelve renal transplants were performed and managed postoperatively at two University-affiliated hospitals between January 1, 2001, and December 31, 2003. The patients received corticosteroids and Sirolimus, with delayed introduction of cyclosporine when the serum creatinine had decreased below 2.5 mg/dL. Two groups of patients were discriminated: group 1 received Basiliximab 20 mg on day 0 and day 4 (n = 283); group 2 recipients with a high panel of reactive antibody (PRA > 20%) and retransplant patients received rATG for induction (n = 129) for a maximum of 2 weeks postoperatively. The incidence of rejection was 14.5% for group 1 vs. 8.5% for group 2 patients. To avoid confounding variable associated with the rejection treatment, any patient with rejection was excluded for statistical analysis, as were patients with follow- up less than 30 days. The final study group for analysis included 350 patients: 235 with Basiliximab induction (group 1) and 115 rATG induction (group 2). The mean follow-up was 21.8 +/- 11 months. Differences in the incidences of postoperative hernia, wound infections, or lymphoceles requiring any form of drainage were analyzed for statistical significance using the chi-square test.

RESULTS

The percentage of patients with wound complications was 26.0% versus 39.1% (P < .025) for group 1 versus group 2, respectively. Incisional hernias occurred in 10.6% versus 18.3% patients (P < .05), wound infections in 11.1% versus 16.5% (P = NS), and lymphoceles in 10.6% versus 15.9% (P = NS) for the two groups, respectively.

CONCLUSIONS

rATG-induced renal transplants recipients treated with sirolimus, cyclosporine, and steroids show a significantly increased incidence of postoperative incisional hernias and a trend toward a greater number of lymphocele and wound infection complications.

摘要

目的

随机对照研究表明,接受西罗莫司治疗的肾移植患者围手术期伤口并发症的发生率增加。本研究分析了兔抗胸腺细胞球蛋白(rATG)对这些术后并发症的影响。

方法

2001年1月1日至2003年12月31日期间,两所大学附属医院共进行了412例肾移植手术并进行术后管理。患者接受皮质类固醇和西罗莫司治疗,当血清肌酐降至2.5mg/dL以下时延迟引入环孢素。区分两组患者:第1组在第0天和第4天接受20mg巴利昔单抗(n = 283);第2组为高反应性抗体(PRA> 20%)的受者和再次移植患者接受rATG诱导(n = 129),术后最多2周。第1组的排斥反应发生率为14.5%,第2组患者为8.5%。为避免与排斥反应治疗相关的混杂变量,任何发生排斥反应的患者均被排除在统计分析之外,随访时间少于30天的患者也被排除。最终用于分析的研究组包括350例患者:235例接受巴利昔单抗诱导(第1组)和115例接受rATG诱导(第2组)。平均随访时间为21.8±11个月。使用卡方检验分析术后疝气、伤口感染或需要任何形式引流的淋巴囊肿发生率的差异,以确定其统计学意义。

结果

第1组和第2组伤口并发症患者的百分比分别为26.0%和39.1%(P <.025)。两组患者的切口疝发生率分别为10.6%和18.3%(P <.05),伤口感染发生率分别为11.1%和16.5%(P =无统计学意义),淋巴囊肿发生率分别为10.6%和15.9%(P =无统计学意义)。

结论

接受西罗莫司、环孢素和类固醇治疗的rATG诱导的肾移植受者术后切口疝的发生率显著增加,并且淋巴囊肿和伤口感染并发症的数量有增加的趋势。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验